

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application No.	09/525,998
Filing Date:	03/15/2000
First Named Inventor	Hauptmann
Group Art Unit	1646
Examiner Name	E. O'Hara

Attorney Docket No. 98-385-E

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		Number	Kind Code ² (if known)			
EPA		6,294,352		Hauptmann et al.	09-25-01	RECEIVED

JAN 15 2003

TECH CENTER 1600/2900


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
EPA		SELMAY et al., "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage in Vitro", Annals of Neurology 23(4):339-346 (1988).
		SELMAY et al., "Proliferation of Astrocytes in Vitro in Response to Cytokines: A Primary Role for Tumor Necrosis Factor," J. Immunol. 144(1):129-135(1990).
		SECKINGER et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 α and 1 β But Not Tumor Necrosis Factor α ," J. Exp. Med. 139(5):1541-1545 (1987).
		SECKINGER et al., "A Urine Inhibitor of Interleukin 1 Activity That Blocks Ligand Binding", Immunol. 139(5):1546-1549 (1987).
		SECKINGER et al., "Characterization of a Tumor Necrosis Factor α (TNF- α) Inhibitor: Evidence of Immunological Cross-Reactivity with the TNF Receptor," Proc. Natl. Acad. Sci. USA 87:5188-5192 (1990).
		SECKINGER et al., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor α Inhibitor", The Journal of Biological Chemistry, vol. 264, No. 20 Issue of July 15, pp.11966-11973, 1989.
		SMITH et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins", Science 248:1019-1023 (1990).
		SMITH et al., "Species Specificity of Human and Murine Tumor Necrosis Factor", J. Biol. Chem. 261(32):14871-14874 (1986).
↓		SOCHER et al., "Antibodies Against Amino Acids 1-15 of Tumor Necrosis Factor Block its Binding to Cell-Surface Receptor", Proc. Natl. Acad. Sci, vol. 84, pp. 8829-8833, December 1987.

Examiner Signature	Eileen B. O'Hara	Date Considered	2/21/03
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231



Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket No. 98-385-E

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Eileen B. O'Hara	Date Considered	2/21/03
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC, 20231